4SC AG (VSC) said study results due by the end of next month may help the German biotechnology company secure a licensing deal for its experimental rheumatoid arthritis medicine, Vidofludimus.

4SC needs a partner to fund the last and most expensive round of human trials required for approval, Chief Executive Officer Ulrich Dauer said in an interview. A possible deal hinges on results from a mid-stage clinical trial that are expected by the end of June, Dauer said. He declined to say how many companies Martinsried, Germany-based 4SC is in talks with, saying the number is “more than two but less than 10.”